Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy

Learn more about:
Related Clinical Trial
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance Integrated Cancer Repository for Cancer Research Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments Magnetic Resonance Imaging of Gynecologic Malignancies Involving the Vagina Immediate Vaginal Reconstruction After Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function Sexual Rehabilitation Programme After Radiotherapy for Gynaecological Cancer Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer Internet-based System for Cancer Patients to Self-report Toxicity Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy Lymphoscintigraphy in Patients With Vaginal Cancer Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer Pelvic Fractures and Radiation Therapy for Cervical Cancer Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer

Brief Title

Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy

Official Title

Phase I Pilot Study Evaluating Vaginal Dilator Use and Toxicity Following Vaginal Brachytherapy

Brief Summary

      This randomized, pilot phase I trial studies whether phone or email reminders increases
      vaginal dilator use in patients with endometrial, cervical, or vaginal cancers after they
      undergo brachytherapy. Brachytherapy is a type of internal radiation which uses radioactive
      material placed directly into or near a tumor to kill tumor cells. A reminder program may
      help increase use of vaginal dilators and decrease long-term side effects following

Detailed Description


      I. Evaluate whether vaginal dilator adherence is improved with additional reminder phone
      calls and/or email reminder survey.


      I. Evaluate whether there are differences in the length of vaginal canal between the
      non-intervention and intervention groups. Evaluate rates of gynecologic, urinary, and
      gastrointestinal toxicity.

      OUTLINE: Patients are randomized to 1 of 3 arms.

      ARM I: Patients receive no additional reminders.

      ARM II: Patients receive a reminder email survey every 2 weeks for 1 year after completing

      ARM III: Patients receive a reminder email survey as in Arm I and 4 additional phone calls at
      4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.

      After completion of study, patients are followed up at 10-14 weeks, 5-7 months, 8-10 months,
      11-13 months, 15-17 months, 19-21 months, and 23-25 months post treatment.

Study Phase

Phase 1

Study Type


Primary Outcome

Vaginal dilator adherence, measured by the average number of times per week patient uses a form of vaginal dilation

Secondary Outcome

 Vaginal canal length


Cervical Cancer


survey administration

Study Arms / Comparison Groups

 Arm I (no intervention)
Description:  Patients receive no additional reminders.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

September 2014

Completion Date

October 23, 2020

Primary Completion Date

January 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Patients with gynecologic cancer who are undergoing vaginal brachytherapy as part of
             their treatment

          -  Patients cannot have previously received pelvic external beam radiation or
             brachytherapy. Patients may be enrolled while undergoing vaginal brachytherapy
             radiation treatment.

          -  Patients should have a life expectancy of at least 1 year

          -  No Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status

          -  No organ and marrow function requirements

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who have received prior pelvic external beam radiation or brachytherapy will
             be excluded

          -  No restrictions regarding use of other investigational agents

          -  No exclusion requirements due to co-morbid disease or intercurrent illness

          -  No investigational agent, so no exclusion requirements regarding history of allergic
             reactions attributed to compounds of similar chemical or biologic composition to
             investigational agent or device

          -  No exclusion criteria relating to concomitant medications

          -  No exclusion criteria for pregnant or nursing patients from participating in this
             study (Of note, pregnant patients will not be treated with vaginal brachytherapy, a
             requirement for enrolling on this study)




18 Years - N/A

Accepts Healthy Volunteers



Elizabeth Kidd, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Stanford University


 National Cancer Institute (NCI)

Study Sponsor

Elizabeth Kidd, Principal Investigator, Stanford University Hospitals and Clinics

Verification Date

August 2021